Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.
InvestorsHub on MSN
Recursion Pharmaceuticals rises 7% after reporting strong mid-stage data in FAP study
Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its ...
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...
Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback